Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. reports developments as a clinical-stage biotechnology company advancing non-viral DNA technologies for immunotherapy and vaccines. Its lead candidate, IMNN-001, is a DNA-based interleukin-12 immunotherapy being developed for localized treatment of newly diagnosed advanced ovarian cancer through the OVATION clinical program.
Company news commonly covers clinical data from OVATION studies, Phase 3 development activity, financial results and business updates, and portfolio work around the TheraPlas platform for cytokine and therapeutic-protein delivery and the PlaCCine platform for viral-antigen delivery. Updates also include capital discipline, organization changes, and presentations of translational or proof-of-concept data.
IMUNON, Inc. (NASDAQ: IMNN) announced the grant of stock options and restricted stock totaling 23,000 shares to incentivize four new employees. The inducement options allow for the purchase of 19,000 shares at an exercise price of $1.40, the closing price on December 13, 2022. These options will vest over three years, while the restricted stock vests after one year. IMUNON focuses on DNA-based immunotherapy and vaccines, with its lead program, GEN-1, in Phase II for advanced ovarian cancer treatment. The company aims to leverage its technological platforms for innovative treatments across various diseases.
IMUNON, Inc. (NASDAQ: IMNN) presented its innovative PLACCINE vaccine modality at the World Vaccine & Immunotherapy Congress in San Diego. The presentation highlighted proof-of-concept data demonstrating immunogenic responses and durable viral clearance from SARS-CoV-2 in animal models. IMUNON's non-viral, plasmid DNA vaccine showed effective results and stability for up to six months. The PLACCINE platform offers advantages such as a durable immune response, safe delivery, and flexible manufacturing, aiming to revolutionize vaccine development.
IMUNON (NASDAQ: IMNN) announced participation in A.G.P.’s Biotech Conference from November 30 to December 1, 2022. Dr. Corinne Le Goff and Mr. Jeffrey Church will represent the company in one-on-one virtual investor meetings. Investors interested in meeting with IMUNON management can contact their A.G.P. representative. The company's lead program, GEN-1, is an innovative DNA-based immunotherapy targeting advanced ovarian cancer, currently in Phase II trials. More details can be found in IMUNON's corporate presentation linked in the announcement.
IMUNON (NASDAQ: IMNN) announced a $375,000 investment in Transomic Technologies, a private firm specializing in CRISPR and gene expression tools. This strategic move aims to enhance IMUNON's PLACCINE DNA vaccine platform by utilizing Transomic's vector construction services for developing plasmids. Executive Chairman Michael H. Tardugno will join Transomic's board. The investment supports ongoing progress in IMUNON's DNA vaccine development against infectious diseases like SARS-CoV-2, showcasing the platform's rapid adaptability to emerging variants.
IMUNON, Inc. (NASDAQ: IMNN) reported its Q3 2022 financial results, showing a net loss of $6.1 million ($0.87 per share) compared to $5.4 million ($0.94 per share) in Q3 2021. Operating expenses rose by 21% to $6.3 million. Key highlights include the completion of enrollment in the Phase I/II OVATION 2 study for GEN-1 in advanced ovarian cancer and promising results from preclinical studies of its PLACCINE vaccine technology. The company’s cash runway extends into 2025, bolstered by recent capital raises. Topline results from GEN-1 are expected in H1 2024.
IMUNON (NASDAQ: IMNN) has signed an agreement with Acuitas Therapeutics to evaluate the use of Acuitas' proprietary lipid delivery technology with IMUNON's PLACCINE nucleic acid vaccine constructs. This collaboration aims at expanding applications of PLACCINE, which has shown promise in non-human primate studies against SARS-CoV-2. The PLACCINE platform features multiple coding regions for broader immunity and is designed for easy modification to create vaccines for various infectious diseases. IMUNON continues to advance its innovative therapies leveraging its unique delivery systems.
Imunon, Inc. (NASDAQ: IMNN) will hold a conference call on November 14, 2022, at 11:00 a.m. ET to report third-quarter financial results for the period ending September 30, 2022. The company will also update on its clinical development of GEN-1, a DNA-based immunotherapy for advanced ovarian cancer currently in Phase II trials, and its preclinical studies of PLACCINE, aimed at advancing vaccine technology.
Join the call by dialing 866-777-2509 or access it via imunon.com.
Imunon, Inc. (NASDAQ: IMNN) has appointed James E. Dentzer to its Board of Directors as of October 3, 2022. Dentzer, CEO of Curis, Inc., brings over 20 years of biopharmaceutical experience, enhancing the Board to nine members. His leadership experience includes roles at Dicerna and Valeritas. Dentzer aims to support Imunon's clinical programs in immune-oncology and infectious diseases, particularly the advanced development of GEN-1 for ovarian cancer.
Imunon, Inc. (NASDAQ: IMNN) reports promising partial results from a non-human primate study evaluating its PLACCINE vaccine as a potential alternative to mRNA vaccines. In the study, Cynomolgus monkeys showed comparable immunogenicity and viral clearance after vaccination with PLACCINE and a commercial mRNA vaccine. The PLACCINE technology, which uses a synthetic DNA delivery system, demonstrated stability and potential safety advantages. The study underlines the capability of PLACCINE to target viral mutations and enhances efficacy through potent immune modifiers.
Imunon, Inc. (NASDAQ: IMNN) announced that its Compensation Committee approved the grant of inducement stock options and restricted stock grants to two new hires during Q3 2022. The stock options allow purchasing 8,500 shares at an exercise price of $1.65, equal to its closing stock price on September 27, 2022. Vesting occurs in thirds over three years, fully exercisable by September 2025. The restricted stock grants total 2,250 shares, vesting on the one-year anniversary of each employee's start date.